Replies to post #164743 on Biotech Values

[DewDiligence]

Re: Interim phase-2 data on VX-135 + Daclatasvir

VRTX reports SVR4 rate of 83% (10/12) in high-dose cohort of open-label phase-2 study of VX-135 + BMY’s Daclatasvir in treatment-naïve GT1 patients:

http://finance.yahoo.com/news/vertex-announces-sustained-viral-response-133000898.html

Of the 12 patients in the 200mg* cohort of VX-135, one patient dropped out because of an SAE and one patient completed treatment but relapsed or didn’t respond to treatment.

The data from the 100mg cohort of VX-135 are worse (see press release). I stand by the assertion in #msg-90498491.

*FDA has a clinical hold on the 200mg dose of VX-135.